We're sorry, but the page you are looking for could not be found. Please check the URL or try using the search bar to find what you're looking for. If you believe you've reached this message in error, please contact our support team for assistance.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance at www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.